Medios Reports Strong Financial Growth for 2025

Medios AG, a prominent player in the Specialty Pharma sector in Europe, reported a notable increase in financial performance for 2025. The company's annual report highlights a 10.4% revenue growth, bringing it to €2.1 billion, and a significant 17.8% rise in EBITDA pre1 to €93.1 million. Medios also improved its EBITDA pre1 margin from 4.2% to 4.5%.

The Pharmaceutical Supply and newly introduced International Business segments were key contributors to this growth. The International Business segment significantly impacted results with revenues of €169.2 million. Despite a slight decline in EBITDA pre1 for the Patient-Specific Therapies segment, overall profitability improved, with earnings per share increasing to €0.61.

Looking forward, Medios anticipates further revenue and margin growth in 2026, projecting revenues between €2.0 billion and €2.12 billion and an EBITDA pre1 margin reaching 4.8%.